
Aignostics is an AI-powered company transforming drug development and improving patient outcomes through precision medicine. They offer a range of products including Foundation Models and the Atlas H&E-TME profiling application, supported by custom services for target and biomarker discovery, translational research, and digital diagnostics. The company emphasizes its deep biomedical expertise, advanced machine learning capabilities, and collaborations with academic institutions. Aignostics, a spin-off from Charité Berlin, has offices in Berlin and New York, and is certified with ISO 13485 and 27001, with a GCP-ready clinical trial platform. They have raised $55 million in funding and employ over 120 people.

Aignostics is an AI-powered company transforming drug development and improving patient outcomes through precision medicine. They offer a range of products including Foundation Models and the Atlas H&E-TME profiling application, supported by custom services for target and biomarker discovery, translational research, and digital diagnostics. The company emphasizes its deep biomedical expertise, advanced machine learning capabilities, and collaborations with academic institutions. Aignostics, a spin-off from Charité Berlin, has offices in Berlin and New York, and is certified with ISO 13485 and 27001, with a GCP-ready clinical trial platform. They have raised $55 million in funding and employ over 120 people.
Headquarters: Berlin and New York
Founded: 2018 (spun out 2020)
Sector: AI-powered computational pathology / biotechnology
Recent raise: $34M Series B (Oct 29, 2024)
Total disclosed funding: ≈ $55M
Employees: ≈ 137
Translating complex biomedical imaging data into actionable insights for precision medicine and drug development.
2018
Biotechnology
€5,000,000
€14,000,000
$34,000,000
Participants included Mayo Clinic, HTGF and existing investors
“Includes strategic and healthcare-focused investors such as ATHOS, Mayo Clinic, Wellington Partners, Boehringer Ingelheim Venture Fund, HTGF and IBB Ventures”
| Company |
|---|
Why us?
We believe that AI has the potential to revolutionize how cancer and other complex diseases are diagnosed and treated. Its impact, however, depends on high-quality data and a rigorous, transparent approach to model development. Our role is to make that possible.
Aignostics is a spin-off from one of Europe’s largest and most prestigious university hospitals (Charité), with employees in Berlin and New York. We have received over $50M in funding from leading investors and are a growing team of over 100 interdisciplinary professionals. We work with academic partners as well as leading global life sciences companies.
You will lead the Public API & Integrations team in our Backend Department, owning the APIs, user management, and workload scheduling systems that power our core B2B platform. As a hands-on Engineering Manager, you grow a high-performing team while ensuring the operational excellence and reliability that our enterprise customers in healthcare depend on.
This is a unique opportunity to join a fun, diverse, and growing team of 100+ software engineers, applied scientists, biologists, and pathologists to shape the next generation of cancer treatments. You will be part of a driven community that works in an agile, supportive, and interdisciplinary research environment where your results make a difference to patients. In our established startup, you have the opportunity to grow personally and technically, take on significant responsibilities, and benefit from a dynamic work environment.
At Aignostics, we believe that fighting cancer is a job for people of all identities, backgrounds, and cultures. We value and celebrate diversity and inclusion and are committed to offering equal employment and promotion opportunities for all applicants and employees.
Where your expertise is needed
What we are looking for
Ideally, You Also Have
Our offer
We are an international, interdisciplinary team that is powering the next generation of precision medicine and advancing the fields of AI and pathology.